VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan

VERAXA has received Scientific Advice from the Paul-Ehrlich-Institute providing an initial derisking of the development path of its BiTAC-TCE program.

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.